
|Articles|February 1, 2003
FDA clinical trial: Myopia study shows benefits of wavefront-guided ablations
Orlando-Six-month results from an FDA clinical trial indicate that customized wavefront-guided LASIK for treatment of myopia with the WavePrint system (VISX) is associated with safe and effective outcomes exceeding FDA targets. The wavefront-guided LASIK is also effective for minimizing increases in higher-order aberrations that can accompany conventional LASIK.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies
3
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
4
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for Demodex Blepharitis
5



























